Dissemin is shutting down on January 1st, 2025

Published in

Wiley, Liver International, 8(42), p. 1891-1901, 2022

DOI: 10.1111/liv.15320

Links

Tools

Export citation

Search in Google Scholar

Outcome of liver cancer patients with SARS‐CoV‐2 infection: An International, Multicentre, Cohort Study

Journal article published in 2022 by Sergio Muñoz‐Martínez ORCID, Victor Sapena ORCID, Alejandro Forner ORCID, Jordi Bruix ORCID, Marco Sanduzzi‐Zamparelli ORCID, José Ríos ORCID, Mohamed Bouattour ORCID, Mohamed El‐Kassas ORCID, Cassia R. G. Leal, Tudor Mocan ORCID, Jean‐Charles Nault ORCID, Rogerio C. P. Alves, Helen L. Reeves ORCID, Leonardo da Fonseca ORCID, Ignacio García‐Juárez ORCID and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractBackground & AimsInformation about the impact of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population.MethodsMulticentre retrospective, cross‐sectional, international study of liver cancer patients with SARS‐CoV‐2 infection registered between February and December 2020. Clinical data at SARS‐CoV‐2 diagnosis and outcomes were registered.ResultsTwo hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS‐CoV‐2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow‐up of 7.20 (IQR: 1.84–11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS‐CoV‐2‐related. Forty (18.4%) HCC patients died within 30‐days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24–12.74], 11.76% [95% CI 4.73–22.30], 20.69% [95% CI 11.35–31.96] and 34.52% [95% CI 17.03–52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 (95% CI 0.49–4.31; p = .5032) in BCLC‐B versus 0/A, and 3.13 (95% CI 1.29–7.62; p = .0118) in BCLC‐C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS‐CoV‐2 infection.ConclusionsThis is the largest cohort of liver cancer patients infected with SARS‐CoV‐2. It characterizes the 30‐day mortality risk of SARS‐CoV‐2 infected patients with HCC during this period.